Mark Thursz is professor of hepatology in the Division of Digestive Diseases and Head of the Department of Metabolism, Digestion & Reproduction in the Faculty of Medicine at Imperial College London.
Prof Thursz is a clinical hepatologist with inpatient beds and a clinic at St Mary’s Hospital. He was educated at King’s College London and trained in Gastroenterology and Hepatology at St Mary’s being appointed as senior Lecturer and honorary consultant in 1997.
Prof Thursz runs a translation research programmes in alcohol-related liver disease and hepatitis B virus infection. He ran the NIHR-HTA funded Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial which explored the utility of existing treatments for alcoholic hepatitis and is now involved in a portfolio of trials in alcohol-related liver disease. Recently granted an MRC Stratified Medicine award he is now exploring novel biomarkers for diagnosis, prognosis and risk of infection in this condition. He is chief investigator for the NUC-B trial (funded by NIHR-EME) and a co-investigator on the PROLIFICA Programme for hepatitis patients in Sub-Saharan Africa.
Prof Thursz was Secretary-General of the European Association for Study of the Liver 2011-13. He is currently Director of the Imperial College Biomedical Research Centre and Trust Research Director for Imperial College Healthcare NHS Trust